HRTX peer analysis
Heron Therapeutics (HRTX) against its competitors: price, today's move, 1-year return and market value side by side.
HRTX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| CHRS Coherus Oncology | $0.73 | -10.35% | -41.93% | $120.23M |
| EPRX Eupraxia | $7.44 | 0.27% | 36.15% | – |
| IVVD Invivyd | $0.57 | -4.91% | -62.76% | $173.97M |
| MDWD MediWound | $14.10 | 0.14% | -19.70% | $202.90M |
| NTHI NeOnc | $3.74 | 7.16% | -63.04% | $107.90M |
| OABI OmniAb | $5.20 | -1.98% | 281.16% | $767.23M |
| PLX Protalix BioTherapeutics | $2.89 | 12.45% | 31.05% | $231.24M |
| SLS SELLAS Life Sciences | $8.40 | -2.10% | 445.28% | $1.75B |
| TARA Protara Therapeutics | $2.42 | -3.59% | -42.42% | $145.97M |
| HRTX Heron Therapeutics | $0.37 | 26.48% | -66.31% | $70.36M |
- HRTX's peers: CHRS (Coherus Oncology), EPRX (Eupraxia), IVVD (Invivyd), MDWD (MediWound), NTHI (NeOnc), OABI (OmniAb), PLX (Protalix BioTherapeutics), SLS (SELLAS Life Sciences).
Updated 2026-11-10 15:47 UTC